Immunohistochemical analysis of p181NK4C and p14ARF protein expression in 117 oligodendrogliomas: Correlation with tumor grade and clinical outcome

Archives of Pathology and Laboratory Medicine

Volumn 126, Issue 1, 2002, Pages 42-48

  Korshunov, Andrey ^a   Golanov, Andrey ^a  

^a BURDENKO NEUROSURGICAL INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOREACTIVITY; OLIGODENDROGLIOMA; PROTEIN EXPRESSION; BRAIN TUMOR; CELL NUCLEUS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; ULTRASTRUCTURE;

CDKN2C PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; ENZYME INHIBITOR; PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN;

ADULT; BRAIN NEOPLASMS; CELL CYCLE PROTEINS; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P18; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OLIGODENDROGLIOMA; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEINS;

EID: 0036007218     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
2. Oligodendrogliomas, part II: A new grading system based on morphological and imaging criteria
3. Oligodendroglioma: An appraisal of recent data pertaining to diagnosis and treatment
4. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
5. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
6. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
7. Specific genetic predictors of chemotherapeutic response and survival in patients with naplastic oligodendrogliomas
8. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay
9. Alteration of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas and mixed oligoastrocytomas
10. Distinct versus redundant properties among members of the INK4 family of cyclin-dependent kinase inhibitors
11. p18 tumor suppressor gene and progression of oligodendrogliomas to anaplasia
12. Identification of 2 distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors
13. Homozygous deletion of the CDKN2C/p181NK4C gene on the short arm of the chromosome 1 in anaplastic oligodendrogliomas
14. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas
15. CDKN2/p16 predicts survival in oligodendrogliomas: Comparison with astrocytomas
16. p53 gene mutation and ink4a-arf deletion appear to be 2 mutually exclusive events in human lioblastoma
17. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities
18. p14ARF deletion and methylation in genetic pathways to glioblastomas
19. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas
20. Promoter hypermethylation and homozygous deletion of p14ARF and p161NK4a genes in oligodendrogliomas
21. The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas
22. The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma: An analysis of 91 cases
23. Prognostic value of tumour-associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: An analysis of 168 cases
24. Regression trees for censored data
25. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas
26. Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: A study of 89 cases
27. Prognostic relevance of TP53 mutation, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas
28. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis
29. Analysis of proliferation and apoptosis in brain gliomas: Prognostic and clinical value
30. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
31. High topoisomerase II alpha expression associates with high proliferation rate and poor prognosis in oligodendrogliomas
32. Clinico-pathological study of forty-four histologically pure supratentorial oligodendrogliomas
33. Evaluation of cell proliferation, epidermal growth factor receptor and bcl-2 immunoexpression as prognostic factors for patients with World Health Organization grade 2 oligodendrogliomas
34. Prognostic factors in oligodendrogliomas
35. Vascular endothelial growth factor expression in oligodendrogliomas: A correlative study with Saint-Anne malignancy grade, growth fraction and patient survival
36. Proliferation and cell death in oligodendrogliomas
37. p27/kip1 expression in oligodendrogliomas and its possible prognostic role
38. Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors
39. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin dependent kinases CDK4 and CDK6
40. Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development
41. Expression of INK4 inhibitors of cyclin D-dependent kinases during mouse brain development
42. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus
43. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas